HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.